Pancreatic Cancer News and Research

RSS

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

Scientists discover breast cancer cells that dodge immune system, promote tumor growth

Scientists discovered a new way breast cancer cells dodge the immune system and promote tumor growth, providing a fresh treatment target in the fight against the disease. While comparable mechanisms to avoid the immune system have been identified in mice with breast and other cancers, the study tested human breast tumor cells, putting researchers closer to understanding how the disease progresses in real patients.

2 Feb 2011

Tarceva Phase III EURTAC study in NSCLC patients with EGFR activating mutations meets primary endpoint

Genentech, a member of the Roche Group and OSI Pharmaceuticals, a wholly owned subsidiary of Astellas U.S. Holding Inc., a holding company owned by Astellas Pharma Inc., today announced that an independent data monitoring committee has recommended that the Phase III EURTAC study be stopped early because the study met its primary endpoint.

28 Jan 2011

AB Science initiates recruitment in masitinib phase 3 study in severe persistent asthma

AB Science SA, a pharmaceutical company specialising in the research, development and commercialisation of protein kinase inhibitors (PKIs), announced today the recruitment of the first patient in the phase 3 study evaluating masitinib in severe persistent asthma.

27 Jan 2011

FDA grants BioSante Orphan Drug designation for Melanoma Cancer Vaccine

BioSante Pharmaceuticals, Inc. today announced the receipt of Orphan Drug designation for its Melanoma Cancer Vaccine in the treatment of stage IIb to IV melanoma, from the FDA's Office of Orphan Products Development. Melanoma is the most deadly form of skin cancer.

25 Jan 2011

PharmaEngine presents PEP02 phase II studies in gastric and pancreatic cancers at ASCO 2011

PharmaEngine, Inc. announced today that two phase II studies of PEP02 (liposome irinotecan) in gastric and pancreatic cancer studies were presented at the 2011 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO) in San Francisco, CA, USA.

25 Jan 2011

Threshold reports positive results from TH-302 Phase 1/2 clinical trial in pancreatic cancer

Threshold Pharmaceuticals, Inc. today announced updated Phase 1/2 clinical trial results related to the Company's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the ASCO Gastro Intestinal Cancers Symposium that took place in San Francisco from January 20-22, 2011.

24 Jan 2011

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.

23 Jan 2011

Immunomedics reports encouraging results from Y-90-labeled clivatuzumab tetraxetan study in pancreatic cancer

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that repeated therapy cycles of its proprietary antibody, clivatuzumab tetraxetan, labeled with yttrium-90 plus low-dose gemcitabine, extended median overall survival.

21 Jan 2011

Novel FAK inhibitors targeting binding site of VEGFR-3 reduce growth of pancreatic cancer cells

CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, today presented research results at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco demonstrating that novel FAK inhibitors targeting the binding site of vascular endothelial growth factor receptor 3 (VEGFR-3) reduced the growth of pancreatic cancer cells in vitro and in vivo.

21 Jan 2011

Additional data from HyperAcute Pancreas cancer immunotherapy Phase 2 trial to be presented at ASCO 2011

NewLink Genetics Corporation today announced that additional data from its Phase 2 clinical trial of the company's investigational HyperAcute® Pancreas cancer immunotherapy will be presented during a poster session at the American Society of Clinical Oncology 2011 Gastrointestinal Cancers Symposium in San Francisco, California.

21 Jan 2011

Researchers discover several key mutations in pancreatic neuroendocrine tumors

Through a grant provided by the Caring for Carcinoid Foundation, researchers at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center have discovered several key mutations in pancreatic neuroendocrine tumors.

21 Jan 2011

Scientists decipher genetic code for a pancreatic cancer type

Scientists at Johns Hopkins have deciphered the genetic code for a type of pancreatic cancer, called neuroendocrine or islet cell tumors. The work, described online in the Jan. 20 issue of Science Express, shows that patients whose tumors have certain coding "mistakes" live twice as long as those without them.

21 Jan 2011

Precision Therapeutics to present pancreatic cancer data at 2011 ASCO GI Symposium

Precision Therapeutics, will present pancreatic cancer data based on Precision's ChemoFx in-vitro chemosensitivity test at the 2011 American Society of Clinical Oncology GI Symposium, January 20-22 in San Francisco, California.

20 Jan 2011

MD Anderson receives $150 million grant from Khalifa Foundation for cancer research

The Khalifa bin Zayed Al Nahyan Charity Foundation is granting $150 million to The University of Texas MD Anderson Cancer Center to support genetic-analysis based research, diagnosis and treatment of cancer.

20 Jan 2011

Researchers discover how Ras oncogene chooses a signaling pathway

The National Cancer Institute estimates that more than 43,000 Americans were diagnosed with pancreatic cancer last year and more than 36,000 died from the disease. Despite advances in genetic science showing that the Ras oncogene is mutated in virtually all pancreatic cancers, scientists have been frustrated by the complexity of the signaling pathways in humans, which make it difficult to pinpoint potential therapeutic targets.

20 Jan 2011

Data on Ensituximab for treatment of pancreatic and colorectal cancers to be presented at ASCO 2011

Neogenix Oncology announced today that Dr. Luis Diaz of The Johns Hopkins University Hospital will present data from Ensituximab, the company's novel, therapeutic antibody to treat pancreatic and colorectal cancers. The presentation is scheduled at the American Society of Clinical Oncology (ASCO) 2011 Gastrointestinal Cancers Symposium to be held January 20-22, 2011 at the Moscone Center in San Francisco, CA, USA.

19 Jan 2011

NCI sponsors fourth REOLYSIN clinical trial in pancreatic cancer

Oncolytics Biotech Inc. announced today that the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute (NCI), which is part of the National Institutes of Health, has agreed to sponsor a 2-Arm randomized Phase II study of carboplatin, paclitaxel plus REOLYSIN® versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer.

18 Jan 2011

Noninvasive radiofrequency fields and targeted gold nanoparticles effective in controlling pancreatic tumors

Kanzius Cancer Research Foundation announces research conducted in the Kanzius/Curley Lab at The University of Texas M.D. Anderson Cancer Center has been published in the December 2010 issue of the American Association of Cancer Research's Clinical Cancer Research journal.

14 Jan 2011

MGH researchers discover massive overexpression of DNA sequences in cancer cells

Massachusetts General Hospital Cancer Center researchers have discovered a previously unknown feature of common tumor cells - massive overexpression of certain DNA sequences that do not code for proteins.

14 Jan 2011

Research study to develop rapid, inexpensive blood screening test for early diagnosis of pancreatic cancer

A clinical research study to develop a rapid and inexpensive blood screening test for the early diagnosis of pancreatic cancer has been launched by Henry Ford Health System and the Barbara Ann Karmanos Cancer Institute.

14 Jan 2011

Pancreatic Cancer News and Research

Further Reading

Scientists discover breast cancer cells that dodge immune system, promote tumor growth

Tarceva Phase III EURTAC study in NSCLC patients with EGFR activating mutations meets primary endpoint

AB Science initiates recruitment in masitinib phase 3 study in severe persistent asthma

FDA grants BioSante Orphan Drug designation for Melanoma Cancer Vaccine

PharmaEngine presents PEP02 phase II studies in gastric and pancreatic cancers at ASCO 2011

Threshold reports positive results from TH-302 Phase 1/2 clinical trial in pancreatic cancer

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

Immunomedics reports encouraging results from Y-90-labeled clivatuzumab tetraxetan study in pancreatic cancer

Novel FAK inhibitors targeting binding site of VEGFR-3 reduce growth of pancreatic cancer cells

Additional data from HyperAcute Pancreas cancer immunotherapy Phase 2 trial to be presented at ASCO 2011

Researchers discover several key mutations in pancreatic neuroendocrine tumors

Scientists decipher genetic code for a pancreatic cancer type

Precision Therapeutics to present pancreatic cancer data at 2011 ASCO GI Symposium

MD Anderson receives $150 million grant from Khalifa Foundation for cancer research

Researchers discover how Ras oncogene chooses a signaling pathway

Data on Ensituximab for treatment of pancreatic and colorectal cancers to be presented at ASCO 2011

NCI sponsors fourth REOLYSIN clinical trial in pancreatic cancer

Noninvasive radiofrequency fields and targeted gold nanoparticles effective in controlling pancreatic tumors

MGH researchers discover massive overexpression of DNA sequences in cancer cells

Research study to develop rapid, inexpensive blood screening test for early diagnosis of pancreatic cancer

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News